$10.57
13.66% yesterday
Nasdaq, May 20, 10:10 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$10.57
-1.36 11.40% 1M
-5.38 33.73% 6M
-2.65 20.05% YTD
-9.68 47.80% 1Y
-4.09 27.90% 3Y
-9.61 47.61% 5Y
-1.44 11.99% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.27 13.66%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Market capitalization $909.52m
Enterprise Value $742.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.99
P/S ratio (TTM) P/S ratio 20.80
P/B ratio (TTM) P/B ratio 4.23
Revenue (TTM) Revenue $43.72m
EBIT (operating result TTM) EBIT $-343.67m
Free Cash Flow (TTM) Free Cash Flow $-286.52m
Cash position $512.20m
EPS (TTM) EPS $-3.87
P/E forward negative
P/S forward 7.91
EV/Sales forward 6.46
Short interest 28.43%
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
92%
Hold
8%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
44 44
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 139 139
78% 78%
318%
- Research and Development Expense 247 247
33% 33%
564%
-344 -344
31% 31%
-786%
- Depreciation and Amortization 0.01 0.01
94% 94%
0%
EBIT (Operating Income) EBIT -344 -344
30% 30%
-786%
Net Profit -331 -331
38% 38%
-758%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
7 days ago
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –
Neutral
GlobeNewsWire
8 days ago
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics -
Neutral
GlobeNewsWire
13 days ago
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Heal...
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 270
Founded 2005
Website www.syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today